IGHE and allergic disease: The authors found that n-3 PUFA supplementation showed a clear reduction in the primary outcome of any allergy (medically diagnosed IgE mediated) in children aged 12–36 months (RR: 0.66 [0.44 to 0.98]; two RCTs; 823 children), but not beyond 36 months (RR: 0.86 [0.61 to 1.20]; one RCT, 706 children).